Literature DB >> 18765310

The hemostatic system and malignancy.

Dorothy M Adcock1, Louis M Fink, Richard A Marlar, Federica Cavallo, Maurizio Zangari.   

Abstract

There is an intimate relationship between the processes involved in malignancy and hemostasis. The mechanisms by which malignancy promotes thrombosis are reviewed herein. Emphasis, however, is placed upon the potential mechanisms by which the hemostatic system modulates malignant potential of tumors. Both thrombotic and nonthrombotic processes related to the enhancement of tumor growth, angiogenesis, and metastases are presented. Also reviewed are the effects of anticoagulants such as vitamin K antagonists, heparin, and other glycosaminoglycans on survival of patients with cancer. As new anticoagulants and targeted anticancer therapies are developed, we can expect the interactions between coagulation and tumor biology to be an evolving and productive area for breakthroughs in basic science and clinical applications.

Entities:  

Mesh:

Year:  2008        PMID: 18765310     DOI: 10.3816/CLM.2008.n.030

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN: 1557-9190


  2 in total

1.  Soluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies.

Authors:  Elodie Ducros; Shah Soltan Mirshahi; Anne-Marie Faussat; Pezhman Mirshahi; Sophie Dimicoli; Ruoping Tang; Julia Pardo; Jdid Ibrahim; Jean-Pierre Marie; Amu Therwath; Jeannette Soria; Massoud Mirshahi
Journal:  Cancer Med       Date:  2012-07-23       Impact factor: 4.452

2.  Fatal paraneoplastic embolisms in both circulations in a patient with poorly differentiated neuroendocrine tumour.

Authors:  A Busch; S Tschernitz; A Thurner; R Kellersmann; U Lorenz
Journal:  Case Rep Vasc Med       Date:  2013-12-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.